The region was an epicenter of suffering, not yet an epicenter of care.
Em maio de 2021, a América Latina e o Caribe ultrapassaram um milhão de mortes confirmadas pela COVID-19 — quase 30% de todas as fatalidades registradas no mundo até aquele momento. A tragédia não era apenas epidemiológica: era também uma expressão brutal das desigualdades globais, em que regiões com menos recursos enfrentavam o vírus com apenas 3% de sua população vacinada, enquanto nações mais ricas já haviam imunizado dezenas de por cento de seus cidadãos. A humanidade se deparava, mais uma vez, com a velha pergunta sobre o que significa pertencer a um mundo comum quando o acesso à proteção é tão profundamente desigual.
- A América Latina atingiu 1.001.404 mortes confirmadas, com a OMS alertando que o número real pode ser duas ou três vezes maior — uma crise invisível dentro de uma crise já devastadora.
- O Brasil, com 446 mil mortes e uma média de 2 mil óbitos diários, concentrava o epicentro mais agudo da tragédia, enquanto seu presidente enfrentava investigação parlamentar pela condução da pandemia.
- Com apenas 3% da população vacinada frente a mais de 40% nos Estados Unidos e 20% na Europa, a região vivia uma disparidade de acesso que transformava a pandemia em um espelho das desigualdades globais.
- Farmacêuticas anunciaram a doação de 3,5 bilhões de doses a países de baixa renda até 2022, e o FMI propôs um plano de 50 bilhões de dólares para vacinar 60% da população mundial — mas promessas e realidade ainda guardavam uma distância perigosa.
- Com 142 mil novos casos diários — alta de 10% em uma semana — e quase 3.900 mortes por dia na região, o vírus acelerava enquanto a resposta vacinal mal engatinhava.
Em uma sexta-feira de maio de 2021, a América Latina e o Caribe cruzaram um limiar sombrio: um milhão de mortes confirmadas pela COVID-19. O número representava quase 30% de todas as fatalidades registradas no mundo até aquele instante — uma concentração de perda sem precedentes em uma única região. A Organização Mundial da Saúde advertia, porém, que os dados oficiais provavelmente subestimavam o verdadeiro custo em duas ou três vezes.
O peso da tragédia não era distribuído de forma equânime. Brasil, México, Colômbia, Argentina e Peru respondiam por cerca de 90% das mortes regionais, mesmo representando apenas 70% da população. O Brasil, com 446 mil óbitos e uma média de quase 2 mil mortes diárias, carregava o fardo mais pesado — e seu presidente, Jair Bolsonaro, enfrentava uma investigação parlamentar sobre a condução da crise. No conjunto da região, a pandemia não dava sinais de recuo: 142 mil novos casos por dia, alta de 10% em uma semana, e quase 3.900 mortes diárias.
O capítulo mais perturbador era o da vacinação. Apenas 3% da população latino-americana havia recebido ao menos uma dose. Nos Estados Unidos, esse índice superava 40%; na Europa, 20%. Carissa Etienne, diretora da Organização Pan-Americana da Saúde, convocou a região a deixar de ser epicentro do sofrimento para se tornar epicentro da vacinação.
No horizonte, havia promessas. Pfizer, Moderna e Johnson & Johnson anunciaram, em cúpula do G20 em Roma, a doação de 3,5 bilhões de doses a países de baixa renda até 2022. O Fundo Monetário Internacional propôs um plano de 50 bilhões de dólares para vacinar ao menos 60% da população global até o fim do ano. Eram gestos de envergadura — mas entre o anúncio e a seringa no braço de quem mais precisava, o vírus continuava seu curso implacável.
On a Friday in May 2021, Latin America and the Caribbean crossed a threshold that had seemed unimaginable just months before: one million confirmed deaths from COVID-19. The region had recorded 1,001,404 fatalities across 31.6 million detected cases, according to the AFP news agency. That single figure represented nearly 30 percent of all pandemic deaths recorded globally at that moment—a staggering concentration of loss in one part of the world. The World Health Organization cautioned, however, that official numbers likely understated the true toll by a factor of two or three.
The burden was not evenly distributed. Five countries—Brazil, Mexico, Colombia, Argentina, and Peru—accounted for nearly 90 percent of the region's deaths, even though they represented only 70 percent of its population. Brazil alone had passed 446,000 deaths, with the country recording an average of nearly 2,000 deaths per day in the week leading up to that milestone. Mexico followed with 221,080 deaths, Colombia with 83,233, Argentina with 73,391, and Peru with 67,253. The scale of Brazil's crisis was particularly acute: it held the grim distinction of the continent's highest daily mortality rate, a fact that took on added weight as the country's president, Jair Bolsonaro, faced investigation by Congress over his handling of the pandemic.
Across the broader region—33 countries and territories in total—the pandemic showed no signs of slowing. The average daily death toll stood at nearly 3,900, a one percent increase from the previous week. New infections were climbing faster still, averaging 142,000 per day, a ten percent jump week over week. The virus was accelerating even as the region struggled to mount a vaccination response.
That struggle was the story's most troubling dimension. Only three percent of Latin America and the Caribbean's population had received a vaccine dose by late May. The disparity with wealthier regions was stark and indefensible. In the United States, more than 40 percent of the population had received at least one dose. In Europe, the figure exceeded 20 percent. In Africa, it had barely reached two percent. Carissa Etienne, director of the Pan American Health Organization, spoke to the crisis with measured urgency: the region was being hit hard by the pandemic, and it was suffering not only in health but in its economies and entire societies. She called for Latin America to become not just an epicenter of suffering but an epicenter of vaccination.
There were gestures toward a solution. Three major pharmaceutical manufacturers—Pfizer and BioNTech, Moderna, and Johnson & Johnson—announced at a G20 summit in Rome that they would donate 3.5 billion vaccine doses to lower-income countries between 2021 and 2022. Pfizer would supply two billion doses, Moderna up to 995 million, and Johnson & Johnson up to 500 million. About 1.3 billion doses would arrive in 2021, with the remainder following in 2022. The companies specified that low-income countries could purchase vaccines at cost, while middle-income countries would receive reduced pricing.
The International Monetary Fund proposed an even more ambitious framework: a 50-billion-dollar financing plan designed to vaccinate at least 60 percent of the global population by year's end and begin the path toward pandemic control. Kristalina Georgieva, the IMF's managing director, presented the proposal at the World Health Summit, also held in Rome as part of the G20 meetings. The plan, she said, set clear objectives, assessed financing needs, and outlined practical steps forward.
Yet proposals and pledges, however substantial, could not immediately close the gap between the vaccinated and the unvaccinated. In Africa, a study published in The Lancet found that patients with severe COVID-19 were dying at higher rates than anywhere else on earth, likely because health infrastructure was simply inadequate to the crisis. The IMF emphasized that meeting global vaccination targets would require not just donations of excess doses but also the removal of barriers to the free movement of raw materials and finished vaccines across borders. The arithmetic was clear: without dramatic acceleration, the pandemic would continue to claim lives in Latin America and beyond for months to come.
Citas Notables
This pandemic is far from over and is hitting Latin America hard, affecting our health, economies, and entire societies. The region must be an epicenter not of suffering but of vaccination.— Carissa Etienne, director of the Pan American Health Organization
Our proposal sets objectives, assesses financing needs, and defines pragmatic actions.— Kristalina Georgieva, managing director of the International Monetary Fund
La Conversación del Hearth Otra perspectiva de la historia
Why did Latin America get hit so much harder than other regions?
The deaths were concentrated in five countries with large populations and weaker health systems. Brazil alone had nearly half a million deaths. But the real problem was what came next—the region couldn't get vaccines fast enough.
Three percent vaccination seems impossibly low. What was happening with supply?
The wealthy countries had already locked up most of the doses. The US was at 40 percent, Europe at 20 percent. Latin America was competing for scraps while the virus kept spreading.
Did anyone acknowledge how unfair that was?
Yes. The Pan American Health Organization director said the region needed to be an epicenter of vaccination, not just an epicenter of suffering. But saying it and doing it are different things.
What about the vaccine companies—were they helping?
They pledged 3.5 billion doses over two years, which sounds enormous until you realize it was meant for all low-income countries globally, not just Latin America. And it wouldn't arrive fast enough to stop what was already happening.
So what was the actual human cost?
Over a million confirmed deaths, but the WHO said the real number was probably two or three times higher. Brazil was losing 2,000 people a day. Those are the people behind the statistics.
Did anyone have a plan to fix it?
The IMF proposed a 50-billion-dollar financing plan to vaccinate 60 percent of the world by year's end. But that was a proposal, not a reality. The region was still dying while the world debated how to help.